Pershing Square Inc. on Alcon Inc.

Pershing Square believes Alcon offers an attractive opportunity to invest in a high-quality medical technology business at an unusually depressed valuation. The company reported strong second-quarter operating performance, including meaningful margin expansion and earnings above expectations, and increased its full-year guidance to 12% to 15% constant-currency EPS growth. Despite this momentum, Alcon trades at approximately 17 times earnings, its lowest historical valuation and a substantial discount to the high-20s earnings multiple it has averaged since becoming publicly traded. Pershing Square attributes much of the valuation discount to broader weakness in European medical technology equities rather than deterioration in Alcon's underlying business. The fund expects sustained mid-teens earnings growth over the next three to five years, complemented by the potential for a substantial valuation multiple recovery. The combination of earnings compounding and multiple expansion is expected to generate meaningful long-term shareholder returns.